Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Combination Effect of Prominin1 (CD133) Suppression and Oxaliplatin Treatment in Colorectal Cancer Therapy

Zahra Asadzadeh
,
Behzad Mansoori
ORCID logo ,
Ali Mohammadi
,
Tohid Kazemi
,
Ahad Mokhtarzadeh
,
Dariush Shanehbandi
,
Nima Hemmat
ORCID logo ,
Afshin Derakhshani
ORCID logo ,
Oronzo Brunetti
ORCID logo ,
Sahar Safaei
,
Marjan Aghajani
,
Souzan Najafi
,
Nicola Silvestris
* ORCID logo ,
Behzad Baradaran
*
Version 1 : Received: 18 July 2020 / Approved: 19 July 2020 / Online: 19 July 2020 (21:01:21 CEST)

A peer-reviewed article of this Preprint also exists.

Asadzadeh, Z.; Mansoori, B.; Mohammadi, A.; Kazemi, T.; Mokhtarzadeh, A.; Shanehbandi, D.; Hemmat, N.; Derakhshani, A.; Brunetti, O.; Safaei, S.; et al. The Combination Effect of Prominin1 (CD133) Suppression and Oxaliplatin Treatment in Colorectal Cancer Therapy. Biomedicine & Pharmacotherapy 2021, 137, 111364, doi:10.1016/j.biopha.2021.111364. Asadzadeh, Z.; Mansoori, B.; Mohammadi, A.; Kazemi, T.; Mokhtarzadeh, A.; Shanehbandi, D.; Hemmat, N.; Derakhshani, A.; Brunetti, O.; Safaei, S.; et al. The Combination Effect of Prominin1 (CD133) Suppression and Oxaliplatin Treatment in Colorectal Cancer Therapy. Biomedicine & Pharmacotherapy 2021, 137, 111364, doi:10.1016/j.biopha.2021.111364.

Abstract

Colorectal cancer (CRC) is considered as one of the leading types of cancer in the world. CD133, as a cancer stem cell marker, has a pivotal role in the development of drug resistance, migration, and stemness properties of CRC cells. This study designed to check the combined effect of CD133siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in HT-29 cell line.MTT assay was performed to define the combined effect of CD133siRNA and Oxaliplatin on the viability of HT-29 cells. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The ability of cell migration was tested by wound healing assay as well. Also, colony formation and sphere formation were conducted to assess the stemness properties in the combination group. Flow cytometry was conducted to investigate the apoptosis, cell cycle, and surface expression of CD133 in different groups. Finally, the expression of migration-, and stemness-associated genes were measured by qRT-PCR. We indicated that silencing of CD133 reduces the migration and stemness properties of colorectal cancerous cells. This suppression makes HT-29 cells more sensitive to Oxaliplatin and reduces the effective dose of this chemical drug. Therefore, the suppression of CD133 in combination with Oxaliplatin treatment might be a promising therapeutic approach in the treatment of colorectal cancer.

Keywords

Colorectal cancer; CD133; siRNA; Oxaliplatin; combination therapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.